218 related articles for article (PubMed ID: 31676785)
1. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract][Full Text] [Related]
2. Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct.
Singhi AD; Wood LD; Parks E; Torbenson MS; Felsenstein M; Hruban RH; Nikiforova MN; Wald AI; Kaya C; Nikiforov YE; Favazza L; He J; McGrath K; Fasanella KE; Brand RE; Lennon AM; Furlan A; Dasyam AK; Zureikat AH; Zeh HJ; Lee K; Bartlett DL; Slivka A
Gastroenterology; 2020 Feb; 158(3):573-582.e2. PubMed ID: 31678302
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
4. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
5. Gene Rearrangement and Expression of PRKACA and PRKACB Govern Morphobiology of Pancreatobiliary Oncocytic Neoplasms.
Itoh T; Omori Y; Seino M; Hirose K; Date F; Ono Y; Mizukami Y; Aoki S; Ishida M; Mizuma M; Morikawa T; Higuchi R; Honda G; Okamura Y; Kinoshita K; Unno M; Furukawa T
Mod Pathol; 2024 Jan; 37(1):100358. PubMed ID: 37871652
[TBL] [Abstract][Full Text] [Related]
6. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
[TBL] [Abstract][Full Text] [Related]
8.
Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
[TBL] [Abstract][Full Text] [Related]
9. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
[TBL] [Abstract][Full Text] [Related]
11. The Use of Fluorescence
Weiel JJ; Forgo B; Sage J; Rangaswami A; Hazard FK
Ann Clin Lab Sci; 2022 May; 52(3):475-483. PubMed ID: 35777788
[TBL] [Abstract][Full Text] [Related]
12. The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.
Reid LM; Sethupathy P
Hepatology; 2016 Feb; 63(2):662-4. PubMed ID: 26505878
[No Abstract] [Full Text] [Related]
13. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
[TBL] [Abstract][Full Text] [Related]
14. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
[TBL] [Abstract][Full Text] [Related]
15. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
[TBL] [Abstract][Full Text] [Related]
16. Investigation of -PRKACA/-PRKACB fusion genes in oncocytic tumors of the pancreatobiliary and other systems.
Maimaitiaili Y; Fukumura Y; Hirabayashi K; Kinowaki Y; Naito Y; Saito A; Rong L; Nakahodo J; Yao T
Virchows Arch; 2022 Dec; 481(6):865-876. PubMed ID: 36152045
[TBL] [Abstract][Full Text] [Related]
17. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
[TBL] [Abstract][Full Text] [Related]
18. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A (
Karamafrooz A; Brennan J; Thomas DD; Parker LL
J Proteome Res; 2021 Oct; 20(10):4815-4830. PubMed ID: 34436901
[TBL] [Abstract][Full Text] [Related]
19. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
[TBL] [Abstract][Full Text] [Related]
20. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
